Abstract: The minimum error entropy (MEE) criterion closely relies on the quadratic information potential (QIP) estimates of Renyi’s entropy. Nevertheless, the ...

Abstract: This paper introduces an online approach for identifying time-varying subspaces defined by linear dynamical systems. The approach of representing linear systems by non-parametric subspace ...

is the Verge’s weekend editor. He has over 18 years of experience, including 10 years as managing editor at Engadget. While there is plenty of criticism to be hurled at what music the algorithm serves ...

This program inputs an integer value n and uses different JavaScript loop structures to compute three results: (1) the nth factorial using a while loop, (2) the sum of the first n numbers using a ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Finish the year with a clearer view of the freight landscape in the December Edge Report from C.H. Robinson. From tracking to triggering: Supply chain visibility is becoming an execution engine Supply ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Delta hopes to use AI-driven pricing for 20% of tickets by year's end Senator Ruben Gallego called Delta's practice 'predatory pricing' The new AI-pricing strategy offers a glimpse into the future of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...